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Abstract
Purpose. Improvements in the systemic management of Ewing’s sarcoma of bone over the last 20 years have led to a
dramatic improvement in survival. The corollary is that treatment of the primary disease requires re-evaluation, since a
signi® cant number of patients still suffer local relapse.
Patients. The effect of radiation dose on local control was reviewed in a series of 96 patients treated between 1967 and
1986. Seventy-four had no metastases at presentation (M0), 22 had metastases (M1). The 5-year survival of all patients
was 28%, and of M0 patients alone 37%. Although these ® gures are poor by today’s standards, they are consistent with
published studies whose patients were enrolled during the same calendar period. Although most deaths occurred by 5
years, survival continued to fall beyond 10 years, which has implications for follow-up in future studies.
Results. The local control (LC) rate at 5 years was 56% for all patients and for M0 patients analyzed separately. There
was no difference in either LC or survival between the ® rst and second decades of the study. Primary site was a signi® cant
determinant of survival and local control, with better outcome for limb tumours compared to pelvic primaries.
Chemotherapy also had a major effect on LC. Radiotherapy improved the probability of LC. Omission of radiotherapy,
or a dose , 40 Gy, was ineffective. In the dose range 40± 66 Gy, there was no evidence of a dose± response relationship.
Key words: Ewing’s sarcoma, local control, radiotherapy dose± response.
Introduction
Ewing’s sarcoma is the second commonest tumour
of bone in children with an annual UK incidence of
approximately 1.7 cases per million, representing
1± 2% of childhood tumours,
1 and between 6± 15%
of all primary bone tumours.
2 It arises almost exclu-
sively in children and young adults. Although not a
common tumour by adult standards, its importance
lies in the age of population affected and its
potential curability.
The role of radiotherapy in the management of
Ewing’s sarcoma has changed completely since
James Ewing ® rst described a `diffuse endothelioma
of bone’.
3 Ewing’s sarcoma is essentially a systemic
disease requiring systemic treatment. Before chemo-
therapy became available 20± 30 years ago, long-
term survival rates were as poor as 10%.
4 Outcome
was determined by metastatic disease, with control
at the primary site being of less importance. Since
the introduction of intensive combination chemo-
therapy, survival has improved considerably, with
some reports of long-term survival being as high as
50± 70%.
5,6 As chemotherapy has reduced death
from metastatic disease, local control (LC) has once
again become more important.
In the management of Ewing’s sarcoma, a num-
ber of unresolved issues persist in the integration of
the treatment modalities, including the roles of
radiotherapy and surgery, and the scheduling of
radiotherapy and chemotherapy. An additional im-
portant question which has attracted less attention is
the optimal dose of radiotherapy required to achieve
local control without in¯ icting unacceptable normal
tissue damage. Although Ewing himself observed
response to radiotherapy,
3 there is comparatively
little in the literature on this topic, and all modern
studies are complicated by the fact that chemo-
therapy has a substantial effect on local disease.
This study has examined the effect of radiotherapy
dose on LC, with the objective of contributing
information on dose± response in Ewing’s sarcoma.
Patients and methods
Patient details
All cases of Ewing’s sarcoma of bone referred to the
Royal Marsden Hospital (RMH) during the period
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Table 1. Patient and treatment details recorded
Details recorded
Age, sex
Nature and duration of symptoms at presentation
Site of primary tumour
Presence or absence of metastases
Site or sites of metastases if present
De® nitive surgical procedure*Ð resection, amputation
Radiotherapy detailsÐ dose, fractionation, overall time;
timing with respect to chemotherapy and surgery
Chemotherapy detailsÐ drugs used and duration; timing
with respect to radiotherapy and surgery
Date of relapse
Location of relapseÐ local, and ® rst distant site
Treatment on relapse
Date of death or last follow-up
Local control or notÐ at time of death or last follow-up
*All patients had a diagnostic biopsy.
Radiotherapy dose fractionation
The variation in dose, fractionation and overall
treatment time made direct comparison of dose
equivalence dif® cult and so the nominal standard
dose (NSD) method was chosen to estimate
the relative effect of different dose-fractionation
schedules.
7 This formula uses the relationship
NSD 5 Dose 3 T
2 0.113 N
2 0.24
where NSD is expressed in rets, T is the overall
treatment time in days and N is the number of
fractions. It was assumed that for every course of
radiotherapy including a complete week, a weekend
would also have been included, so that a 30-fraction
course would have taken 42 days. The formula was
used to express treatments as equivalent total doses
at 2 Gy/fraction. However, the NSD method incor-
porates considerable assumptions.
8 The indices in
the equation were originally based on the study of
acute-reacting `normal’ tissues, rather than tumours.
Nevertheless, in at least one study, NSD was found
to ® t clinical tumour data better than the linear-
quadratic model.
9 Although generally preferred, the
more modern linear-quadratic model does not, in its
simplest form, account for differences in overall
treatment time and therefore cannot be applied here
to equate treatment schedules.
10
Data analysis
Patients were categorized into those without metas-
tases at presentation (M0) and those with metas-
tases (M1). Patients with metastases at presentation
had a much shorter survival; the analysis has there-
fore focused on those patients who were M0 at
presentation.
11 Although M1 patients were ana-
lyzed, they have been treated separately. Due to
developments in diagnostic methods, especially CT
scanning, it is likely that staging was more accurate
in the latter part of the study. Thus, it is possible
that some patients classi® ed as M0 early in the study
would really have been M1. For LC, a minimum
period of 3 months was left before recurrence was
monitored, to avoid confusion with failure to
achieve control. Thus, patients dying within this
period were excluded from calculations of LC.
Patients were censored if amputation was performed
for reasons other than local recurrence, or upon
death, since they were no longer `available’ to
develop local recurrence.
In comparing the probability of events in different
patient groups, the log-rank test was used, with LC
and survival probabilities described on a Kaplan±
Meier plot. Where several subsets of a parameter
have a natural order, for example radiotherapy dose
in those patients receiving radiotherapy, a test of
trend across groups was applied, rather than a test of
heterogeneity. Patients were adjusted for known
prognostic variables by strati® cation before compari-
1967± 1986 inclusive were identi® ed using the hos-
pital database and cross-referenced against the
Histopathology Department disease register. All his-
tology was reviewed at the RMH and only those
cases con® rmed as Ewing’s sarcoma were retained.
Four small round cell tumours of bone without a
more speci® c diagnosis and 10 Ewing’s sarcomas
arising in soft tissue have been excluded from the
analysis.
Information on patients was obtained retrospec-
tively as shown in Table 1. It proved impossible to
collect details of tumour size or volume. In the
earlier years of the study, CT and magnetic reson-
ance imaging (MRI) were not available, so measure-
ments of the extent of the intramedullary
component and soft tissue extension could not be
made. For patients treated later, where scanning
had been carried out, tumour size had not been
recorded. Levels of lactate dehydrogenase (LDH)
had not been measured routinely. No attempt was
made to detail the chemotherapy doses because it
was felt that this information might be inaccurate
when collected retrospectively. However, details of
drugs used and intended doses, as well as the timing
of chemotherapy in relation to radiotherapy and
surgery, were collected.
For radiotherapy treatments, details of time, dose
and fractionation were collected. All patients were
treated with megavoltage photons, except for four
patients treated palliatively with low doses
( , 24 Gy, equivalent to 2 Gy/fraction). The mar-
gins of radiotherapy ® elds around the primary tu-
mour could not be extracted retrospectively, partly
because tumour extent could not be accurately as-
sessed. A wide range of doses was found, particu-
larly in the ® rst decade of the series. However, the
wide variation in radiotherapy dose has allowed an
attempt at evaluation of dose± response, which
would have otherwise been impossible.Radiotherapy dose and local control of Ewing’s sarcoma 33
Table 2. Characteristics of patients and treatment: 96
patients, treated 1967± 1986*
Age Range 1± 59 years
Median 16 years
Sex Male 53
Female 43
Site Limbs 50
Arm 15
Leg 35
Pelvis 24
Rest of body 22
Metastases Yes 22
at presentation No 74
Radiotherapy Given 83
Not given 13
Chemotherapy Given 81
Not given 15
De® nitive Resection 19
surgery** Amputation 5
None 72
*Actual numbers are shown.
**All patients had a diagnostic biopsy.
relapse. Although most deaths occurred by 5 years,
a few patients succumbed later; one patient died of
disease in the 11th year after treatment. Of the 22
patients with metastases at presentation, 21 are
known to have died and the other patient was lost to
follow-up with extensive disease.
The LC rates for all patients were 71% (95% CI
60± 80%) at 2 years, 65% at 3 years and 56% (95%
CI 41± 68%) at 5 years. There was no difference in
LC or survival according to sex or age at presen-
tation, and no difference in either LC or survival
between the ® rst and second decades of the study.
For M0 patients the overall 5-year survival was
37% (95% CI 25± 50%), and the 5-year disease-free
survival rate 18% (95% CI 10± 28%). Not surpris-
ingly, the difference in overall survival between M0
and M1 patients was highly signi® cant
(p , 0.0005). Of the 74 M0 patients, 47 have died.
The survival fell to 22% at 8 years, and 16% at 10
years. It should be noted that the number of patients
available `at risk’ was small from 6 years on, but
these late deaths have implications for follow-up in
future studies. The LC rates for M0 patients were
73% (95% CI 61± 83%) at 2 years, 70% at 3 years
and 56% (95% CI 41± 70%) at 5 years (Fig. 2). Two
patients relapsed locally beyond 5 years, at 9 and
10.4 years, respectively, and both developed metas-
tases at the same time.
Eleven patients had symptoms attributable to tu-
mour for over 2 years before presentation (the
longest for 3.5 years). There did not appear to be an
increased risk of metastases at presentation with
longer duration of symptoms, and there was no
difference in LC or survival.
Comparing duration of symptoms, there was no
difference in survival or LC. Eleven patients had
symptoms attributable to tumour for over 2 years
before presentation (the longest for 3Ã years). There
did not appear to be an increased risk of metastases
at presentation with longer duration of symptoms.
For all patients, the site of primary tumour had a
highly signi® cant effect on overall survival
(p 5 0.001, adjusted for extent of disease at presen-
tation), but not on LC, categorizing primary site as:
limbs, axial skeleton or pelvis, in order of reducing
survival. For M0 patients, site had a signi® cant
effect on survival (p 5 0.04). The relative risks of
local failure for the axial skeleton, limbs and pelvis
were 1, 1.6 and 2.2, respectively. These differences
were not statistically signi® cant, because of the small
number of local failure events (26 in this group),
although the magnitude of the effect is consistent
with a clinically important difference.
The administration of chemotherapy appeared to
have a potent effect on LC, reducing the relative risk
of local relapse in M0 patients to 0.53 (95% CI
0.22± 1.26%) (Fig. 3). This was not statistically
signi® cant (p 5 0.14), but very few patients did not
receive chemotherapy, so the numbers in this com-
parison are small, and non-receipt of chemotherapy
son. Where possible, results have been adjusted for
confounding variables, although it is unlikely that
the effects of such factors have been completely
removed. For example, the choice of treatment and
dose, either radiotherapy or chemotherapy, may
have have been in¯ uenced by expected prognosis.
Due to the relatively small size of the cohort, full
analysis via multivariate methods was not possible.
Hazard ratios are referred to as relative risks
throughout.
Results
Ninety-six patients were available in the study co-
hort. Patient characteristics and the treatments they
received are shown in Table 2, and the distribution
of age in Fig. 1. Of the 96 patients, 22 had metas-
tases at the time of presentation (M1). In 11, only
one organ was affected; in the other 11, metastatic
disease affected two or more systems. Lung was
involved in 15 patients, bone in 8, bone marrow in
7, lymph nodes in 2 and liver in 2. No patient had
central nervous system disease. Four patients had
malaise or fever at presentation, although only two
of these had metastases, so these symptoms do not
necessarily indicate widespread disease.
The overall 5-year survival of all patients
(M0 1 M1) was 28% (95% con® dence interval (CI)
19± 39%), and the 5-year disease-free survival was
14% (95% CI 8± 22%). Sixty-eight patients in the
study are known to have died, 65 from metastatic
disease, two from graft versus host disease following
heterologous bone marrow transplant and one from
chemotherapy-induced sepsis. All three treatment-
related deaths occurred in patients with systemic34 N. G. Burnet et al.
Fig. 1. Age distribution of 96 patients with Ewing’s sarcoma of bone.
Fig. 2. Kaplan± Meier plot of LC for patients with no
metastases at presentation (M0).
Fig. 3. LC for M0 patients according to treatment modality:
radiotherapy (RT) alone, chemotherapy (CT) alone or both.
Numbers in brackets refer to O/N where O 5 number of events
in each group and N 5 number of patients in each group.
may have been related to widespread disease. In this
series, there was no discernible difference in LC or
survival with the number of chemotherapy agents
administered. High-dose chemotherapy with bone
marrow transplantation was not seen to improve LC
or survival but this treatment was reserved for pa-
tients with very extensive disease at presentation or
following relapse. No patients were successfully sal-
vaged after relapse, although one patient survived 5
years.
Surgical resection in M0 patients appeared to
improve LC, with the relative risk of local failure
falling to 0.74 (adjusted for primary site) following
successful removal, but numbers were very small.
The distribution of radiotherapy dose is shown in
Fig. 4, with total doses converted to be equivalent to
2 Gy/fraction. Of the 17 patients in the > 60 Gy
group, 10 received exactly 60 Gy in 30 daily frac-
tions over 6 weeks; the highest dose delivered was
66 Gy. Radiotherapy resulted in an improved proba-Radiotherapy dose and local control of Ewing’s sarcoma 35
Fig. 4. Dose distribution in the 83 patients who received radiotherapy.
Fig. 5. Local control for M0 patients according to radiother-
apy dose, calculated for equivalence to 2 Gy/fraction. Numbers
in brackets refer to O/N where O 5 number of events in each
group and N 5 number of patients in each group.
Table 3. The effect of radiotherapy dose on LC
Relative risk of local failure
(95% CI)
Radiotherapy
dose (Gy) M0 patients All patients
None 1.0 1.0
, 40 0.48 (0.1, 2.21) 0.91 (0.28, 2.89)
40± 49 0.21 (0.06, 0.87) 0.29 (0.09, 0.93)
50± 59 0.21 (0.06, 0.85) 0.31 (0.10, 0.94)
60± 69 0.18 (0.09, 0.87) 0.29 (0.06, 0.85)
p 5 0.04 p 5 0.005
Relative risk is shown for patients strati® ed by primary site.
The p-values apply to test for trend. See also Fig. 5, which
shows the probability of LC with time in M0 patients given
different doses.
bility of overall survival when all patients were con-
sidered (p 5 0.02), with an apparent advantage of
doses > 40 Gy. Considering M0 patients only, the
relative risk of death in those not receiving radio-
therapy was 2.5, although this estimate was based
on only seven patients and was not signi® cant
(p 5 0.15).
However, this effect on survival is likely to have
been caused by omission of radiotherapy from pa-
tients with widespread disease at presentation. The
same argument applies to the effect of radiotherapy
on LC. Omission of radiotherapy, or the delivery of
a low dose, greatly reduced the probability of LC.
LC rates with different radiotherapy doses for M0
patients are shown in Fig. 5. The log-rank test for
trend shows a statistically signi® cant effect for radio-
therapy dose (p5 0.04), shown in Table 3. A dose
of , 40 Gy is associated with a considerably re-36 N. G. Burnet et al.
duced chance of LC, and may not even be suf® cient
for palliation in some cases. All local failures in this
group occurred within 1 year of treatment. A com-
parison of the three groups treated with > 40 Gy
demonstrated no evidence of a dose-response (test
for trend p 5 0.82), although very few local failure
events were seen (only 19 in the M0 group).
Discussion
Progress in the management of Ewing’s sarcoma of
bone over the last 20 years has led to a dramatic
improvement in prognosis, particularly for those
patients who are metastasis free at presentation.
This has refocused attention on the control of local
disease.
12 Ewing originally described the tumour as
being `highly susceptible to radium’.
3 However, a
signi® cant local recurrence rate remains. This has
led to the increased use of surgical resection, with
radiotherapy reserved to follow incomplete surgery,
or when surgical resection is impossible. The radio-
therapy question which has received most attention
in recent years is scheduling with chemotherapy.
However, the issues of radiotherapy dose, and the
dose± response characteristics of this tumour remain
poorly de® ned.
The purpose of this study was to investigate the
effect of radiotherapy dose on local control. There
were 96 patients, which at ® rst sight appears a
reasonable number. However, the high death
rate and losses to follow-up substantially reduced
the number of available local failure `events’, partic-
ularly when adjusting analysis for possible
confounding factors.
Problems of retrospective studies
Drawbacks of retrospective studies include failure
to collect data which are now known to be of
prognostic value, such as tumour volume, the
dif® culty of identifying radiotherapy margins
around the tumour, and incomplete records of the
reasons underlying management decisions. This can
lead to analysis being confounded, where the out-
come of interest has itself in¯ uenced the choice of
treatment.
The time period covered by the study saw
considerable changes in the methods available for
investigating and staging patients, with the intro-
duction of CT and MRI. This did not cause any
apparent problems in the analysis but was partly
responsible for the increased proportion of M1
patients seen in the second decade of the study
(10% rising to 38%), and may have affected man-
agement decisions. Dramatic changes also took
place in chemotherapy schedules, surgical tech-
niques, and planning and delivery of radiotherapy.
All these factors have the effect of increasing hetero-
geneity in the study group, hampering the interpret-
ation of data. However, provided the danger of
over-interpretation is avoided, the advantage of a
study of this sort is the collection of information on
dose± response, without the use of a two dose-level
randomized clinical trial.
Study results
The distribution of age, sex, type and duration of
symptoms, and the distribution of primary site in
our series were typical (Fig. 1, Table 2).
2 Age had
no effect on outcome. This is consistent with other
studies, although in some, older age has been associ-
ated with a worse prognosis.
12,13
The site of the primary tumour proved of major
prognostic signi® cance, in accordance with other
reported experience: limb sites carry a better prog-
nosis than axial skeleton tumours, which in turn are
better than pelvic tumours.
12,14± 16 It may be that site
is really a re¯ ection of the size of tumour at diag-
nosis rather than being an independent prognostic
variable.
17 In the Cooperative Ewing’s Sarcoma
Study (CESS) 81 trial, a Cox regression analysis
identi® ed tumour volume (, or > 100 cm
3) and
histological response to initial chemotherapy as the
major determinants of prognosis. The primary site
was not an independent prognostic factor, probably
because of the link to tumour volume.
17
The presence or absence of metastases at the time
of presentation is a major prognostic factor.
12,15,17
This emphasizes the importance of initial staging,
and the effect that a change in quality of staging
investigations has on comparative results. The poor
outlook of M1 patients was the reason for our
focusing on metastasis-free patients for the assess-
ment of LC. Chemotherapy had a profound effect
on LC (Fig. 3). However, no patients were salvaged
after relapse, which is a manifestation of the failure
of chemotherapy to sterilize bulky disease.
Survival and local control
The rates of both overall survival and LC in the
study were disappointing compared to current stud-
ies. It is reasonable to expect patients treated now to
have long-term survival rates of around 50%, but
such success has been achieved only comparatively
recently.
5,11,17 Our results are comparable with other
studies reporting on patients treated from the 1960s
to the early 1980s.
12,13,18,19 Only the Intergroup
Ewing’s Sarcoma Study (IESS-I) trial which re-
cruited from 1973 to 1978 reported a substantially
higher 5-year survival of 65%, but this was in pa-
tients with localized disease at presentation.
5 In
IESS-II, recruiting from 1978 to 1982, patients with
localized disease excluding pelvic primaries had an
overall 5-year survival of around 70%.
20 The CESS
81 and CESS 86 trials have reported 3-year survival
rates for patients with localized disease of 55% and
62%, also demonstrating the improvement in sur-
vival which has become possible in the last decade.
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LC rates have also been rising in more recent
studies, reaching 3-year LC rates of around 70±
90%.
5,12,17 The local failure rate in CESS 81 was
around 50% and is thought to relate partly to poor
radiotherapy planning.
6,17 Those studies which
cover the early period of chemotherapy, through the
1960s and 1970s, generally report lower rates of
LC, in the range of 40± 50%, and our results are
consistent with these.
16,19
Duration of follow-up
In our study, there was a small rate of attrition due
to relapsing Ewing’s sarcoma extending out to 11
years, which is the typical experience of studies with
long follow-up.
5,12,18 It has occasionally been advo-
cated that disease-free status at 5 years equates to
cure, implying that follow-up need not be continued
beyond this,
13 but to assess true rates of cure cer-
tainly requires longer follow-up. The CESS studies
have tended to report 3-year ® gures, because there
are many more `at risk’ patients and most events
occur within the ® rst 3 years.
17 There is also a
signi® cant incidence of second tumours, partly re-
lated to an underlying predisposition in patients
with Ewing’s sarcoma and partly to treatment, and
there is an appreciable incidence of treatment-
related complications, some of which are fatal.
13,21 It
is therefore mandatory for follow-up to be long
enough to record these events.
Radiotherapy dose± response
In the pre-chemotherapy era, it was noted that doses
of , 40 Gy resulted in frequent local failure, even
though long-term survival was low.
4 More recent
studies have failed to demonstrate a dose± response
above 40 Gy, although it is generally accepted that
higher doses improve LC.
6,17 Our data are entirely
consistent with these reports. In the CESS 81 study
where patients were randomized to receive either
46 Gy or 60 Gy, no dose± response was found, with
local failure just as frequent in the higher dose
group. However, LC rates with radiotherapy were
poor in this trial until centralized planning was
established; this may have confounded any dose
effect which might have been present.
6,17 Lack of
dose± response has also been seen in other stud-
ies.
14,16 In the IESS-I trial, it was felt that this might
have been due to the high incidence of death from
metastatic disease (almost 50% at 3 years) preclud-
ing clinical manifestation of local recurrence.
11
Some justi® cation for higher doses has come from
one study in which LC of bulky tumours
( > 100 cm
3) was improved by doses of 55± 60 Gy.
22
Doses above 60 Gy, in combination with chemo-
therapy, appear to offer no advantage in LC and
have led to impaired functional outcome from nor-
mal tissue damage.
23 The consensus is that doses up
to about 60 Gy are required for macroscopic dis-
ease, although 45 Gy is considered to be adequate
for microscopic disease.
6,17
It is possible that a dose± response does exist but
that the search for it has been confounded by small
numbers and technical problems.
13,14,17 In addition,
a wide variation in intrinsic cellular sensitivity can
lead to dif® culty in establishing a dose± response.
Although in vitro data for Ewing’s sarcoma are lim-
ited, there is a marked spread in sensitivity between
tumours.
24
Assimilating the results from our study and from
many others, there is good evidence that doses
below 40 Gy are ineffective. In our study, in patients
who received no radiotherapy or doses less than
40 Gy, all local failures occurred within 1 year of
treatment. This suggests that reasonably high doses
are required even for palliative treatment, since pa-
tients with metastatic Ewing’s sarcoma may survive
for many months.
Conclusions
In our study, radiotherapy improved the probability
of local control. Omission of radiotherapy or a dose
of less than 40 Gy proved ineffective for LC, so that
low doses may not necessarily be suf® cient for palli-
ation. In the dose range 40± 66 Gy, there was no
evidence to suggest a dose± response.
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